Consequently these previous studies predict a strong survival advantage for G+ CD4+T cells containing the dual construct (CCR5 entry inhibitor + C46 fusion inhibitor), since these have reduced CCR5 expression (due to CCR5 entry inhibitor) and inhibit the viral fusion step of the HIV infection cycle (due to C46 fusion inhibitor), and should therefore be less likely to undergo bystander apoptosis. Here, CCR5 is linked to HIV infectious disease.